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Abstract
Background: High breast density is linked to an increased risk of breast cancer, and correlates with changes in collagen.
In a mouse model of mammary carcinoma in the context of increased collagen deposition, the MMTV-PyMT/Col1a1tm1jae,
there is accelerated mammary tumor formation and progression. Previous gene expression analysis suggests
that increased collagen density elevates expression of PTGS2 (prostaglandin-endoperoxide synthase 2), the
gene for cyclooxygenase-2 (COX-2).
Methods: To understand the role of COX-2 in tumor progression within a collagen-dense microenvironment, we treated
MMTV-PyMT or MMTV-PyMT/Col1a1tm1jae tumors prior to and after tumor formation. Animals received treatment with
celecoxib, a specific COX-2 inhibitor, or placebo. Mammary tumors were examined for COX-2, inflammatory and stromal
cell components, and collagen deposition through immunohistochemical analysis, immunofluorescence, multiplex
cytokine ELISA and tissue imaging techniques.
Results: PyMT/Col1a1tm1jae tumors were larger, more proliferative, and expressed higher levels of COX-2 and
PGE2 than PyMT tumors in wild type (WT) mice. Treatment with celecoxib significantly decreased the induced
tumor size and metastasis of the PyMT/Col1a1 tumors, such that their size was not different from the smaller
PyMT tumors. Celecoxib had minimal effect on the PyMT tumors. Celecoxib decreased expression levels of
COX-2, PGE2, and Ki-67. Several cytokines were over-expressed in PyMT/Col1a1 compared to PyMT, and celecoxib
treatment prevented their over-expression. Furthermore, macrophage and neutrophil recruitment were enhanced in
PyMT/Col1a1 tumors, and this effect was inhibited by celecoxib. Notably, COX-2 inhibition reduced overall collagen
deposition. Finally, when celecoxib was used prior to tumor formation, PyMT/Col1a1 tumors were fewer and smaller
than in untreated animals.
Conclusion: These findings suggest that COX-2 has a direct role in modulating tumor progression in tumors arising
within collagen-dense microenvironments, and suggest that COX-2 may be an effective therapeutic target for women
with dense breast tissue and early-stage breast cancer.
Background
Breast cancer is the most common invasive cancer in
women with upwards of 40,000 deaths annually in the
USA [1]. Women who have over 75 % mammographic
breast density have a more than four-fold increased risk
for developing breast cancer, making it one of the most
significant risk factors for this disease [2–6]. High breast
density correlates with larger amounts of collagen fibers
in the breast tissue [7], and a key feature of this density/
collagen association is the presence of excessive and al-
tered collagen structure and distribution. Our group has
defined changes in collagen structure that manifest as
bundles of straightened and aligned collagen fibers ori-
ented perpendicular to a tumor boundary, termed tumor
associated collagen signature-3 (TACS-3) [8], which are
associated with decreased survival among patients with
breast cancer [9]. In a transgenic mouse model with in-
creased collagen deposition (mouse mammary tumor
virus-polyomavirus middle T/carrying the collagenase
transgene (MMTV-PyMT/Col1a1tm1jae)) the number
and size of tumors and metastases increases three-fold
[8, 10]. Despite the accumulation of data suggesting a
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role for increased collagen in mammary tumor progres-
sion, the molecular mechanisms for the increased risk
and subsequent cancer development are unknown.
We previously found that culture of mammary epithelial
cells in a high-density collagen matrix significantly upre-
gulates prostaglandin-endoperoxide synthase 2 (PTGS2),
the gene for cyclooxygenase-2 (COX-2) [11, 12]. COX-2
over-expression is observed in 40 % of patients with inva-
sive breast carcinoma and correlates with poor prognosis
[13–15]. Unlike the constitutive activity of COX-1, COX-2
is an inducible enzyme that synthesizes prostaglandins,
including prostaglandin E2 (PGE2), and is activated at
sites of injury as part of the inflammation response [16].
Mammographically dense breast tissue has elevated COX-
2 expression compared to breast tissue from women with
low mammographic density [17]. In rodent models of
mammary neoplasms, COX-2 over-expression pro-
motes tumor formation and progression to metastasis,
in addition to increased angiogenesis, cell migration,
and invasion [12, 18–21]. High COX-2 expression cor-
relates with increased levels of aligned collagen and
both are the driving force for the development of ductal
carcinoma in situ in a postpartum mammary gland invo-
lution mouse model. Moreover, treatment with non-
steroidal anti-inflammatory drugs (NSAIDs), which inhibit
cyclooxygenases, reverses this effect [12]. Celecoxib is a
selective NSAID that specifically inhibits COX-2 and is
the only COX-2 inhibitor currently approved by the Food
and Drug Administration (FDA) for use in the USA [22].
Several studies have demonstrated that NSAIDs decrease
the risk of cancer development [23–30]. Specifically, cele-
coxib prevents sporadic colorectal adenoma [31] and sev-
eral clinical trials have evaluated the use of celecoxib
alone or in combination with chemotherapy regimens in
breast cancer settings [13]. Despite these associations, the
role of COX-2 in collagen remodeling and in development
of invasive breast cancer is still unclear.
In this report we tested the hypothesis that breast density
promotes high COX-2 levels, which support tumor growth
and progression. The goal of this study was to describe the
role of COX-2, inflammation, and density in the breast
tumor microenvironment. We found that COX-2 and
PGE2 levels are elevated in the collagen dense (PyMT/
Col1a1) tumors, and COX-2 inhibition with celecoxib
decreases these expression levels. Treatment with cele-
coxib significantly diminished tumor growth and prolif-
eration in the collagen dense tumors. Many cytokines
were over-expressed in PyMT/Col1a1 tumors, and COX-2
inhibition reversed their over-expression. Results from this
cytokine panel led us to look closer at different immune
and stromal cell populations and their response to COX-2
inhibition in PyMT/Col1a1 and wild-type (WT) tumor
microenvironments. We found that macrophage and neu-
trophil recruitment are enhanced in PyMT/Col1a1 tumors
and enhancement was blocked by COX-2 inhibition. In
addition, celecoxib decreased α-SMA+ fibroblast numbers
in PyMT/Col1a1 tumors. Collagen deposition in both
PyMT and PyMT/Col1a1 tumor microenvironments was
diminished with celecoxib; however, normal mammary
glands were not affected by COX-2 inhibition. Together,
these findings suggest that COX-2 has a direct role in
modulating tumor progression in dense matrices, which
promote a more invasive cancer effect. COX-2 may be an
effective therapeutic target for women with dense breast-
tissue-associated breast cancer.
Methods
Mice and trial design
Mice were maintained and bred at the University of
Wisconsin under the oversight of and with the ethical
approval of the University of Wisconsin Animal Use
and Care Committee (approved protocol # M01688).
A therapeutic mouse model was used to evaluate the
effects of high COX-2 expression in an advanced stage
of mammary cancer (Fig. 2a). Nulliparous female
MMTV-PyMT/Col1a1tm1jae, their PyMT counterparts
bearing mammary tumors, Col1a1tm1jae (no tumor),
and their WT littermates were randomly assigned to a
daily treatment of 0.2 mg (linear scale from 600 mg
human dose or 10 mg/kg of body weight) celecoxib
(Pfeizer Inc.) suspended in 5 % methyl cellulose or 5 %
methyl cellulose alone (vehicle) at 11 weeks of age for
a duration of 21 days. Dosage calculations were made
for a 20-g mouse. Tissues were collected for study at
14 weeks of age.
To evaluate the effects of COX-2 inhibition with cele-
coxib in response to collagen density as a preventive breast
cancer therapy, a preventive mouse mammary model was
used (Fig. 8a). Female MMTV-PyMT/Col1a1tm1jae, their
WT counterparts bearing mammary tumors, Col1a1tm1jae
(no tumor), and their WT littermates at 10 days of age were
randomly assigned to treatment with celecoxib suspension
or vehicle. Ten days of age is as early as neonate mice can
be handled for oral administration of their assigned treat-
ment, and is a developmental stage that precedes tumor
formation in this model. First, neonate mice were orally fed
with celecoxib 3.3 mg/kg of body weight (linear scale from
200 mg human dose) or vehicle every other day until they
were weaned at 3 weeks of age. Dosage calculations were
made for a 10-g mouse. At this low dose, celecoxib is
not thought to interfere with development or cause
other physiological complications in the pediatric popu-
lation [32, 33]. At weaning, the dose was increased to
6.7 mg/kg of body weight (linear scale from 400 mg human
dose) every other day until mice reached 9 weeks of age.
Dosage calculations were made for a 20-g mouse. At
9 weeks of age, tumors were clearly palpable, and animals
were killed for tissue analysis.
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Antibodies
The following antibodies were used for immunohistochem-
ical analysis (IHC) and/or immunofluorescence (IF): COX-
2 (Cayman 160126), PGE2 (Abcam ab2318), Ki-67 (Abcam
ab15580), β-NGF (Abcam ab6199), IL-17A-R (LSBio LS-
B6706), F4/80 (AbD Serotec MCA497R), Ly6g (Biolegend
127601), vimentin (Abcam ab92547) and alpha-smooth
muscle actin (α-SMA) (Abcam ab5694).
Histology, immunohistochemistry and
immunofluorescence
For histology the tissues were fixed in 10 % formalin
for 48 h followed by paraffin-embedding (formalin-
fixed paraffin-embedded (FFPE)). Tissue sections were
stained with hematoxylin and eosin (H&E). For IHC,
FFPE tissues were deparaffinized as per standard,
followed by dehydration and antigen retrieval with Citra
Plus (Biogenex HK080-5 K) for 15 minutes, blocking with
BLOXALL, avidin/biotin (Vector SP-6000 and SP-2001,
respectively), and normal serum. Primary antibodies were
incubated either overnight at 4 °C (anti-COX-2 or anti-
PGE2 1:500) or were incubated for 1 h at room
temperature (anti-Ki-67 1:200). Tissue sections were incu-
bated with biotinylated rabbit IgG (Vector, BA-1100) for
10 minutes after 30-minute incubation with R.T.U. Vectas-
tain kit Elite ABC (Vector PK-7100). For IF, tissue sections
were treated as described above for 20 minutes to retrieve
antigens and then were subjected to the TSA Plus kit
for tissue labeling following the manufacturers’ proto-
cols (Perkin Elmer, fluorescein NEL741E001KT, Cy 3.5
NEL744E001KT and Cy 5 NEL745E001KT). Briefly, pri-
mary antibodies were incubated as follows: COX-2
(1:1000, overnight); PGE2 (1:5000, 1 h); β-nerve growth
factor (NGF) (1:6000, O/N); IL17RA (1:10000, 1 h); F4/80
(1:1000, 1 h); Ly6g (1:1000, 1 h); vimentin (1:1000, 1 h);
α-SMA (1:1000, 1 h). Horseradish peroxidase (HRP)-
conjugated anti-rabbit (Abcam, ab7090) or anti-rat
(Abcam, ab7097) was added for 10 minutes after
10 minutes incubation with TSA Plus kit working solu-
tion including the desired fluorophore. Tissues underwent
the antigen retrieval step for 20 minutes if the same tissue
would be subjected to multiple labeling, before counter-
staining with 4',6-diamidino-2-phenylindole (DAPI) for
2 minutes at 1:10000 (Life Technologies, D21490).
Nuance and InForm software
IF and IHC image experiments were acquired using a
Nuance microscope with × 20 objective and software
version 3.0.12 (Perkin Elmer) with analysis as previously
described [34]. Briefly, a spectral library was created
using image cubes to define distinctive spectral curves
for each fluorophore, chromogen, and counterstain to
adjust for background effects and accurately quantify
positive staining of biomarkers using InForm version
1.4.0 software (Perkin Elmer). This software analysis al-
lows objective counting of cell populations and bio-
markers and increases the accuracy of the statistical
analysis. Algorithms for tissue and subcellular compart-
ment separation were created by machine learning and all
algorithms had precision above 95 % (Additional file 1:
Figure S1). Algorithms were created for separating tissue
compartments into stroma and epithelium, and to identify
nuclei to accurately assign associations for positive stain-
ing to a specific compartment in the tumor microenviron-
ment. To create each algorithm, 10 % of the image dataset
was used for each experiment.
Masson’s trichrome and color segmentation software
To assess collagen deposition in the tumor tissue and
mammary glands, Masson trichrome staining (Cancer
Diagnostics Inc., SS1026-MAB-250) was used on paraffin-
embedded sections. Color images were analyzed with FIJI
software and the color segmentation plugin (Daniel Sage,
2008, http://bigwww.epfl.ch/sage/soft/colorsegmentation/)
using the K-means algorithm clustering method. All images
had the same pixel size and so the total area of collagen
could be quantitated as the number of blue pixels over the
total number of pixels per image.
Cytokine array
To describe a cell signaling mechanism for collagen density
changes in response to high COX-2 levels and to COX-2
inhibition, a mouse cytokine ELISA plate array (Signosis,
Sunnyvale, CA, USA) was used. In this quantitative
chemiluminescence plate array, 23 mouse cytokines
were monitored simultaneously for their expression
levels in relation to collagen deposition and COX-2 in-
hibition with celecoxib. The cytokine signal was mea-
sured with a fluorometer (Fluoroskan, Ascent, FL) and
Ascent software version 2.6 (Thermo Scientific). To
compare fold-change differences, data were normalized
to a blank and graphically represented by normalization
to PyMT vehicle cytokine data levels.
Positron emission tomography (PET) imaging and analysis
Highly sensitive and quantitative PET imaging was used
to study potential preventative effects of COX-2 inhibition.
All mice were fasted for 8 h prior to intravenous injection
of approximately 5 MBq of 2′-deoxy-2′-[18F]fluoro-D-glu-
cose (FDG) 1 h before imaging. Mice were anesthetized
with inhalation gas (2 % isoflurane gas mixed with 1 L/mi-
nute of pure oxygen) and kept under a heat lamp during
injection until imaging. Mice were imaged in a prone pos-
ition on a Siemens Inveon Hybrid micro-PET/CT (Siemens
Medical Solutions, Knoxville, TN, USA). A 10-minute PET
scan was acquired and data were displayed as a histogram
in one static frame; data were subsequently reconstructed
using ordered-subset expectation maximization (OSEM) of
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three dimensions followed by the maximum a posteriori al-
gorithm (matrix size = 128, 128, and 159; pixel size = 0.776,
0.776, and 0.796 mm; iterations = 18; subsets = 16; and beta
smoothing factor = 0.004). Data were not corrected for
attenuation or scatter. PET analysis was performed using
Siemens Inveon software (Siemens Medical Solutions).
The data were normalized to animal weight, amount of
injected PET tracer, and tracer decay. A sphere was drawn
and positioned over identified tumors and tumor volume
and mean FDG uptake were calculated by the software.
Statistical analysis
The analyses were performed to study the effect of COX-2
in mammary tumor progression in response to cell matrix
density. Mixed linear models were used to assess differ-
ences between the various factors. The data were tested
for normality and were log transformed as necessary.
Every statistical test was two-sided, and a p value <0.05
was considered statistically significant. All analyses were
performed using the procedure PROC MIXED from the
SAS/STAT® software (version 9.4).
Results
COX-2 expression levels are elevated in collagen-dense
tumors
To assess whether COX-2 is involved in tumor growth and
enhanced in a collagen-dense tumor microenvironment, we
used our previously characterized transgenic mouse model
of increased stromal collagen based on the Col1a1tm1jae
mouse. This transgenic line has a mutation in the collage-
nase cleavage site of the α1 chain of collagen I, leading to
increased collagen accumulation [10]. Mammary tumors
were induced by the expression of the robust transgene,
MMTV-PyMT, in which mammary carcinomas are driven
by expression of the polyoma middle-T antigen, resulting in
a mammary carcinoma that shares many histopathologic
features with progression of human breast cancer [35, 36].
The resulting female progeny of Col1a1/+ x MMTV-PyMT
carry the MMTV-PyMT transgene on either the WT or
Col1a1tm1jae/+ background.
Tissue from 14-week-old nulliparous female mice was
used for quantitative IF to detect COX-2 and its product,
PGE2, to assess expression levels with respect to mam-
mary tumor collagen density. We measured both COX-2
and PGE2 in the stroma adjacent to tumors and epithe-
lium from tumors to see if their expression predomi-
nates within a particular tissue compartment. There
was higher stromal COX-2 expression in the PyMT/
Col1a1tm1jae mouse mammary tumors compared to the
PyMT tumors (Fig. 1a and c). Similarly, in collagen-
dense tumors there was a small increase in stromal
PGE2 expression (Fig. 1b and d). In the absence of tu-
mors, we did not see a significant difference in COX-2
and PGE2 in mammary glands from PyMT mice com-
pared to Col1a1 mice (not shown).
COX-2 inhibition with celecoxib diminishes tumor growth
and progression to metastasis
To test whether COX-2 inhibition reverses COX-2 and
PGE2 expression, we treated PyMT and PyMT/Col1a1
mice with 0.2 mg celecoxib or vehicle (5 % methyl cellu-
lose) for 21 days (Fig. 2a). This dose was selected because
it is comparable to the human dose of 600 mg a day (when
using a linear scale, 10 mg/kg of body weight) and no
serious adverse side effects in humans have been reported
at this dose for this short period. Mice were started on a
daily treatment at 11 weeks of age and tissues were col-
lected at 14 weeks of age. At the 11-week time point,
tumors were established and uniformly palpable among all
experimental animals. Four treatment arms were created
for this study: PyMT vehicle, PyMT celecoxib, PyMT/
Col1a1 vehicle, and PyMT/Col1a1 celecoxib. PyMT/
Col1a1 mice had larger tumors compared to PyMT mice
and COX-2 inhibition with celecoxib diminished tumor
growth only in collagen-dense tumors (Fig. 2b and c).
Next, we collected lung tissue to quantify lung metastasis;
despite a trend toward increased metastasis in PyMT/
Col1a1 mice compared to PyMT mice, there was no
statistically significant difference (Additional file 2: Figure
S2). As there was a significant different in tumor growth,
we measured cell proliferation in these mouse mammary
tumors. IHC for detection of the proliferation marker,
Ki-67, demonstrated that celecoxib diminished prolifera-
tion both in PyMT and PyMT/Col1a1 mammary tumors
(Fig. 2d and e). While COX-2 levels were significantly
increased in PyMT/Col1a1 tumors compared to WT tu-
mors, COX-2 expression was significantly decreased in
PyMT and high-density collagen mouse tumors when
treated with celecoxib (Additional file 3: Figure S3 A-B).
Moreover, PGE2 expression was significantly elevated in
collagen-dense tumors and inhibition with celecoxib re-
versed this effect in both PyMT and PyMT/Col1a1 tumors.
This suggests that COX-2 has a role in tumor growth and
progression and that its inhibition has differential effects in
mammary tumors arising in dense collagen compared to
the WT milieu.
Inflammatory cytokines regulated by density and COX-2
inhibition
Cancer, inflammatory and stromal cells can secrete and
respond to cytokines that stimulate growth, diminish
apoptosis, and enable invasion and metastasis in the
tumor microenvironment. Having demonstrated that
dense collagen tumors have increased expression of
COX-2, and that its over-expression enhanced tumor
growth, cell proliferation, and metastasis, we investigated
the role of COX-2 in inflammation within collagen-
Esbona et al. Breast Cancer Research  (2016) 18:35 Page 4 of 15
dense tumor microenvironments using a quantitative
chemiluminescence assay to detect the expression of 23
cytokines. Samples from three mouse tumors for each of
the study arms were pooled and cytokines were moni-
tored simultaneously for their expression relative to
collagen deposition and COX-2 inhibition with cele-
coxib. Most cytokines were increased two-fold or more
in PyMT/Col1a1 tumors compared to PyMT tumors.
Cytokines with substantially increased expression in-
cluded IL-2 (19-fold), β- NGF (17-fold), IL-4 (13-fold),
platelet-derived growth factor (PDGF) (8.7-fold) and IL-
17A (5-fold) (Fig. 3). COX-2 inhibition with celecoxib
diminished overall cytokine expression levels in both
PyMT and PyMT/Col1a1 mice (Fig. 3). These results
indicate that there is an effect of high collagen density in
altering cytokine expression levels, and that these high
cytokine expression levels are decreased by COX-2 in-
hibition with celecoxib.
To validate the cytokine expression in the epithelium
and stroma of the tumors, we performed quantitative IF
for two highly expressed cytokines. We studied overall
β-NGF distribution in the tumor microenvironment. β-
NGF is secreted by epithelial cells, macrophages, neutro-
phils, and neurons. It is expressed in 80 % of breast
cancers and it activates the survival and proliferation of
tumor cells [37, 38]. Overall, we found that β-NGF ex-
pression was higher in the tumor epithelial compartment
than in the stroma, and that there was more stromal
β-NGF in PyMT/Col1a1 tumors compared to PyMT
tumors. Treatment with celecoxib reversed β-NGF in
PyMT/Col1a1 tumors, within both the epithelial and
stromal compartments (Fig. 4a and c).
Because we observed high levels of IL17A in the
cytokine array data, we characterized the expression
of IL-17A receptor (IL-17A-R) as a measure of cell
populations that may be recruited by this cytokine.
Fig. 1 Cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) levels are elevated in collagen-dense tumors. a, b Immunofluorescence images of
COX-2 or PGE2 (magenta) counterstained with 4',6-diamidino-2-phenylindole (DAPI) (green); ×20 objective, scale bar= 100 um. Composite is zoomed-in
image of area demarked by the yellow window; scale bar= 15 um. c, d Quantitation of several images as shown in a and b. Box plots are overlaid with
violin plots to indicate differences in the density distribution of data points. Raw data are depicted. Epi epithelium, Str stroma. Quantitative values represent
the number of positive stained cells divided by the total number of cells in that compartment. c COX-2 levels are elevated in tumor and stromal cells from
collagen-dense tumors in PyMT/Col1a1 compared to tumors arising in PyMT mice. d PGE2 levels are moderately elevated in PyMT/Col1a1 tumors in cells
in the stromal compartment; *p< 0.05; n = 5 mice; at least 8 image fields analyzed per 2–3 tumors per animal
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We observed that IL-17A-R is mostly expressed by
cell populations in the stromal compartment, and
was significantly elevated in PyMT/Col1a1 tumors
compared to PyMT tumors (Fig. 4b and d). Cele-
coxib treatment inhibited IL-17A-R-expressing cell
populations within the stroma of the collagen-dense
tumor microenvironment (Fig. 4b and d). Together
these findings indicate that tumor density and COX-
2 expression play a role in cytokine expression, per-
haps via inflammatory pathways.
Fig. 2 Celecoxib diminishes PyMT/Col1a1, but not PyMT, tumor growth. a Timeline for the celecoxib therapeutic study. See “Methods” for more
details. b Representative example of tumors arising in collagen-dense mice treated with vehicle or celecoxib. c Quantitation of several tumors
from mice treated with vehicle or celecoxib. Tumor weight is higher in PyMT/Col1a1 tumors when compared to PyMT tumors. Celecoxib delays
tumor growth in mice with collagen-dense tumors. d Immunohistochemical analysis (IHC) of representative tumor sections stained with antibody
against Ki-67 (visualized with 3,3-diaminobenzidine (DAB) (brown)) and counterstained with hematoxylin; ×20 objective; scale bar= 100 um. e Quantitation
of the number of Ki67-positive cells normalized to the total number of cells. Celecoxib treatment diminishes proliferation levels as measured with the Ki-67
marker in both PyMT and PyMT/Col1a1 tumors. Veh vehicle, Clxb celecoxib. Raw data depicted; *p< 0.05, **p< 0.01, ****p< 0.0001; n= 5 mice; at least 8
image fields analyzed per 2–3 tumors per animal
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Collagen-dense tumors and COX-2 regulate macrophage
and neutrophil populations
To characterize cytokine-mediated recruitment of inflam-
matory and stromal cell populations to the tumor micro-
environment, we performed quantitative IF to identify
populations of mature macrophages (F4/80-positive) and
neutrophil granulocytes (Ly6g-positive). Stromal F4/80
macrophages were significantly increased in PyMT/Col1a1
tumors compared to PyMT tumors. Treatment with cele-
coxib diminished F4/80+ macrophage numbers in collagen-
dense tumors (Fig. 5a and c). Moreover, epithelial Ly6g+
neutrophils were also increased in the collagen-dense tu-
mors compared to PyMT tumors and celecoxib diminished
Ly6g+ neutrophil populations only in PyMT/Col1a1 tumors
as well (Fig. 5b and d). These results reinforce the data from
our cytokine array study and suggest that increased tumor
collagen density leads to increased COX-2 function and
recruits macrophages and neutrophils into the collagen-
dense microenvironment.
Collagen-dense tumors and COX-2 regulate fibroblast
populations
Our cytokine array data revealed elevation of several
cytokines and growth factors associated with tumor cell
proliferation and inflammatory response modulation in
the PyMT/Col1a1 tumor microenvironment (Fig. 3). To
determine whether the collagen-dense microenviron-
ment and high COX-2 levels regulate different fibroblast
populations known to secrete such factors, we performed
quantitative IF with vimentin as a general fibroblast
marker and α-SMA as a marker of cancer-associated
fibroblasts (CAF). We observed that stromal vimentin+
fibroblast populations were similar in all treatment arms
of the study. However, there was a trend toward decreased
vimentin+ fibroblast numbers only in the PyMT/Col1a1
tumors with celecoxib treatment (Fig. 6a and c). Notably,
celecoxib decreased α-SMA+ fibroblasts within the PyMT/
Col1a1 tumor microenvironment (Fig. 6b and d). Few cells
that are vimentin-positive or aSMA-positive co-stain for
CD31, indicating that the cells we originally identified as
CAF are not microvasculature (not shown). Nor did the
number of CD31+ cells account for the effect of celecoxib
on tumor regression under high density conditions (not
shown).
As CAF induce higher collagen deposition to alter the
extracellular matrix, and COX-2 inhibition diminishes α-
SMA+ fibroblasts in PyMT/Col1a1 tumors, we character-
ized collagen levels in mammary tumors using Masson’s
trichrome staining. There was more collagen deposited in
PyMT/Col1a1 tumors and COX-2 inhibition by celecoxib-
Fig. 3 Regulation of cytokines by celecoxib in PyMT and PyMT/Col1a1 tumors. Several cytokines are upregulated in PyMT/Col1a1 (HD) mammary
tumors compared to PyMT (wild-type (WT)) tumors. Treatment with celecoxib (CLXB) diminishes cytokine levels in PyMT (WT) and PyMT/Col1a1
(HD) mice. Relative levels of cytokines are represented as the fold-change normalized to PyMT (WT) vehicle (VEH). Cytokines with equal to or
greater than a two-fold change are considered significantly upregulated. Three tumors, each from a single animal, were pooled per treatment arm to
perform the multiplex cytokine ELISA array. TNFα tumor necrosis factor alpha, IGF insulin growth factor, VEGF vascular endothelial growth
factor, IL interleukin, FGFβ fibroblast growth factor beta, IFNy interferon gamma, EGF epithelial growth factor, G-CSF granulocyte-colony
stimulating factor (CSF-2), GM-CSF granulocyte-macrophage colony-stimulating factor (CSF-3), MCP-1 monocyte chemotactic protein 1 (CCL2), MIP-1α
macrophage inflammatory protein 1 alpha (CCL3), SCF stem cell factor, RANTES regulated on activation, normal T cell expressed and secreted (CCL5),
PDGF-ββ platelet-derived growth factor beta-beta, β-NGF nerve growth factor beta
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reversed collagen levels in both PyMT and PyMT/Col1a1
tumors (Fig. 7a and c). To discriminate effects related to
tumor formation vs COX-2 treatment, we stained the
mammary glands of nulliparous mice treated with cele-
coxib or vehicle in PyMT and PyMT/Col1a1 mice. COX-2
inhibition by celecoxib did not affect collagen deposition
in the mammary glands of either PyMT or PyMT/Col1a1
mice (Fig. 7b and d). These results indicate that inhibition
of COX-2 by celecoxib specifically affects the tumors of
PyMT/Col1a1 mice by reducing CAF populations, and by
diminishing the tumor-associated collagen deposition
prevalent in PyMT/Col1a1 tumors.
Administration of celecoxib prior to tumor formation
diminishes tumor growth and number
To study whether celecoxib inhibition of COX-2 expres-
sion in response to collagen density might be effective as
a preventive breast cancer therapy, we treated early post-
natal animals before palpable tumors arose. In the
MMTV-PyMT model, tumors arise at puberty, when the
mammary gland develops. Female PyMT/Col1a1 and
their WT PyMT counterparts at 10 days of age (well
before puberty) were randomly assigned to treatment
with celecoxib or vehicle (Fig. 8a). Mice were treated
until they were 9 weeks of age and their tissues were col-
lected for analysis. PET scans were used to determine
mammary gland tumor weight, number, growth rate,
and volume in PyMT and PyMT/Col1a1 mice with and
without celecoxib treatment. Mice were imaged at
6 weeks and 9 weeks. At 9 weeks of age, mice bearing
collagen-dense tumors had larger tumors when com-
pared to PyMT tumors. Consistent with the above treat-
ment regimen, celecoxib diminished tumor weight only
in PyMT/Col1a1 mice (Fig. 8b). Tumor growth features
Fig. 4 Immunofluorescence (IF) validation of cytokine data in tumor and stroma tissue. a, b Representative IF images of nerve growth factor beta
(β-NGF) or IL-17A receptor (IL-17A-R) (magenta) counterstained with 4',6-diamidino-2-phenylindole (DAPI) (green); ×20 objective; scale bar = 100
um. Composite is an enlarged image of the area demarked by the yellow window; scale bar = 15 um. c Quantitation of β-NGF normalized to the
total number of cells. β-NGF is elevated in the stroma of PyMT/Col1a1 tumors. Celecoxib (Clxb) decreases β-NGF in both the epithelium and
stroma in PyMT/Col1a1 tumors. β-NGF is higher in the tumor epithelium, consistent with its known role in promoting survival and proliferation of
epithelial breast cancer cells. d Quantitation of IL-17A-R normalized to the total number of cells. IL-17AR is elevated in the stroma of PyMT/Col1a1
tumors, consistent with its role in macrophage/neutrophil recruitment. Celecoxib treatment decreases IL-17A-R only in the stroma of PyMT/Col1a1
tumors. Raw data are depicted; *p < 0.05, ***p < 0.001, ****p < 0.0001; n = 5 mice per arm; at least 8 image fields analyzed per 2–3 tumors per
animal; mixed linear model. Veh vehicle
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were measured and compared longitudinally over time
using PET scans, and the number of tumors was counted
at 6 and 9 weeks of age. Histopathological analysis at
9 weeks of age confirmed that each tumor assessed by
PET was indeed a tumor, and not otherwise hypermeta-
bolic tissue (Additional file 4: Figure S4). Over time the
collagen-dense mice developed more tumors than PyMT
mice. Celecoxib reduced tumor numbers only in PyMT/
Col1a1 mice (Fig. 8c and f). In addition, the rate of
increase in tumor volume was enhanced over time in
mice bearing PyMT/Col1a1 tumors compared to PyMT
tumors. Again, celecoxib reduced tumor volume in PyMT/
Col1a1 mice (Fig. 8d). Surprisingly, we did not find dif-
ferences when we measured mean glucose uptake with
18Fluorodeoxyglucose-PET tracer, suggesting that nei-
ther density nor treatment with celecoxib altered glu-
cose metabolism (Fig. 8e).
To further understand the underlying mechanisms of
COX-2 inhibition and its response to the collagen-dense
tumor microenvironment in this early treatment setting,
we measured levels of different cytokines using the multi-
plex ELISA cytokine array described above. The relative
levels of cytokines followed the same trends as in the later
therapeutic study (Fig. 3). Most cytokines had 2-fold in-
creased expression: the greatest increases were in the
expression of epithelial growth factor (EGF) (3.4-fold),
leptin (3.2-fold), IL-1α (3.3-fold), granulocyte macrophage
colony stimulating factor (GM-CSF) (3.7-fold), monocyte
chemotactic protein 1 (MCP-1) (3.1-fold), and β-NGF
(3.8-fold) (Fig. 8g). Collagen-dense tumors tended to ex-
press significantly higher levels of cytokines compared to
WT tumors. Additionally, when PyMT and PyMT/Col1a1
mice were treated with celecoxib, the relative levels of
cytokines declined (Fig. 8g). Similar to the later thera-
peutic study, these results suggest that collagen density
affects expression of cytokines in a manner that is re-
versed by celecoxib. Together, these data indicate that
COX-2 is a significant driver of tumor formation and
Fig. 5 Regulation of macrophages and neutrophils by collagen density and celecoxib. a, b Immunofluorescence images of F4/80+ macrophages
or Ly6g+ neutrophils (magenta), respectively, counterstained with 4',6-diamidino-2-phenylindole (DAPI) (green); ×20 objective; scale bar = 100 um.
c, d Index was calculated by dividing positive-stained cells by total numbers of cells. Raw data are depicted. c Quantitation of total F4/80+ cells
normalized to the total number of cells. F4/80+ macrophage numbers are elevated in the stroma of PyMT/Col1a1 tumors and decreased by treatment
with celecoxib. d Total number of Ly6g+ neutrophils normalized to total number of cells. Ly6g+ neutrophil numbers are elevated in the epithelium of
PyMT/Col1a1 tumors and decreased by treatment with celecoxib (Clxb); **p < 0.01; n = 5 mice per arm; at least 8 image fields analyzed per 2–3 tumors
per animal; mixed linear model. Veh vehicle
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growth in collagen-dense tumors. Celecoxib reverses the
increased tumor progression of the collagen-dense micro-
environment, although it cannot completely prevent
tumor incidence in this genetically driven MMTV-
PyMT mouse model.
Discussion
COX-2 over-expression in breast cancer is associated with
poor patient prognosis and is emerging as a key mediator
of tumor inflammation. Here, we determined the role of
COX-2 in regulating the enhanced tumor formation and
progression that we observed in the collagen-dense tumor
microenvironment. We found that PyMT/Col1a1 tumors
arising in collagen-dense tissue were associated with a more
inflammatory microenvironment than PyMT tumors
arising in WT mice. Over-expression of COX-2 is a
major contributor to the inflammatory milieu of collagen-
dense tumors, and leads to recruitment of tumor-associated
macrophages (TAMs) and tumor-associated neutrophils
(TANs). Subsequently, we demonstrated that we can reverse
recruitment of inflammatory cell populations in the dense
tumor microenvironment by selectively inhibiting COX-2
with celecoxib. In addition, celecoxib reduced collagen de-
position and decreased αSMA+ fibroblasts, mainly in the
PyMT/Col1a1 tumors. These data suggest there may be a
therapeutic opportunity to treat tumors arising in dense
breast tissue with celecoxib. As the clinical findings with cel-
ecoxib as a therapeutic or preventative approach to breast
cancer have been mixed, our data suggest that selection of
the right patients - those with dense breast tissue - may re-
sult in the appropriate context by which treatment with cel-
ecoxib might be more effective.
Consistent with the enhanced inflammatory environment
of the collagen-dense tumors, we observed a dramatic in-
crease in several cytokines in the PyMT/Col1a1 tumors.
Several granulocyte and macrophage-recruiting cytokines,
including GM-CSF, G-CSF, MCP-1, MIP-1α and RANTES
(CCL5), were increased in collagen-dense tumors.
Moreover, there was a strong increase in IL-17A, which
contributes to macrophage and neutrophil recruitment
Fig. 6 Regulation of fibroblasts by collagen density and celecoxib. a, b Immunofluorescence images of vimentin+ fibroblasts or alpha smooth
muscle actin (α-SMA)+ fibroblasts (magenta) counterstained with 4',6-diamidino-2-phenylindole (DAPI) (green); ×20 objective; scale bar = 100 um.
c The number of vimentin+ fibroblasts remains the same regardless of collagen density. Values represent vimentin+ cells normalized to total cell
number. d Celecoxib (Clxb) decreases the number of α-SMA+ fibroblasts in the stroma of PyMT/Col1a1 tumors. Values represent the number of α-
SMA+ cells normalized to the total number of cells. Raw data are depicted; *p < 0.05; n = 5 mice per arm; at least 8 image fields analyzed per 2–3
tumors per animal; mixed linear model. Veh vehicle
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[39]. IL-17A is a pro-inflammatory cytokine that is
secreted by T helper (Th)17 cells and induces the pro-
duction of other cytokines, growth factors, and prosta-
glandins from other cells, including fibroblasts [39].
Also, IL-17A promotes angiogenesis, cell proliferation,
and chemoresistance and it is associated with poor
patient prognosis [40, 41]. We observed increased levels
of IL-17R-A in the stroma of collagen-dense tumors,
and these levels decreased after celecoxib treatment.
Accordingly, decline of IL17A and its receptor expression
levels after treatment with celecoxib was accompanied by
declining populations of F4/80+ macrophages and Ly6g+
neutrophils. Recent findings demonstrate a role for COX-
2 in the immune checkpoint, allowing melanomas to
escape immune surveillance [42]. Based on our findings
that the collagen-dense microenvironment increases
COX-2 and regulates inflammation, it is possible that a
collagen-dense microenvironment will have a role in regu-
lating the immune checkpoint as well.
PDGF-ββ is produced by epithelial and endothelial
cells and stimulates nearby mesenchymal cells, includ-
ing fibroblasts, in a paracrine fashion [43]. Consistent
with this, we observed significant over-expression of
PDGF-ββ in PyMT/Col1a1 tumors compared to PyMT
tumors, and COX-2 inhibition by celecoxib diminished
this effect. COX-2 inhibition with celecoxib decreased
αSMA+ fibroblasts in only the PyMT/Col1a1 tumors,
even though this population was not significantly in-
creased in the PyMT/Col1a1 tumors. CAF secrete ele-
vated levels of many growth factors, including β-NGF.
The continuous secretion of β-NGF activates an auto-
crine loop whereby more fibroblasts are recruited [44].
Additionally, β-NGF can be secreted by epithelial cells,
macrophages, and neutrophils. Interestingly, we found
that stromal β-NGF is elevated only in PyMT/Col1a1
tumors and COX-2 inhibition with celecoxib decreases
β-NGF over-expression in both PyMT and collagen-
dense tumors.
Fig. 7 Celecoxib diminishes collagen deposition in PyMT mammary tumors, but does not affect tumor-free mammary glands. a, b Masson’s
trichrome stain of mammary tumors or mammary glands of nulliparous mice treated with vehicle or celecoxib. Collagen fibers are in blue, cell
nuclei are black and the cell cytoplasm, muscle tissue, and erythrocytes are stained red; ×20 objective; scale bar = 100 um. c, d Quantitation of
Masson’s trichrome, performed as described in “Methods”. a, c There is significantly increased collagen in PyMT/Col1a1 compared to PyMT tumors.
Celecoxib (Clxb) diminishes collagen deposition in both PyMT and PyMT/Col1a1 tumors. b, d There is no significant effect of treatment with celecoxib
in normal, tumor-free mammary glands. Glands in Col1a1 animals tend to have greater collagen accumulation than their wild-type counterparts. Raw
data are depicted; **p < 0.01, p < 0.0001; n = 5 mice per arm for a and c and n = 1 mouse per arm for b and d; a and b are separate animal cohorts,
age is 14 weeks for both animal cohorts; at least 5 image fields analyzed per 2–3 tumors/glands per animal; mixed linear model. Veh vehicle
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Fig. 8 Celecoxib diminishes PyMT/Col1a1 tumor growth when administered prior to tumor formation. a Timeline for the celecoxib preventive
study. See “Methods” for more details. b-e Quantitation of several tumors from PyMT and PyMT/Col1a1 animals, treated with vehicle (Veh) or
celecoxib (Clxb). b Tumor weight is higher in PyMT/Col1a1 tumors (n = 5) when compared to PyMT tumors and celecoxib delays tumor growth in
PyMT/Col1a1 mice. c PyMT/Col1a1 mice develop more tumors than PyMT mice and celecoxib reduces tumor number in PyMT/Col1a1 mice. d Tumor
volume is higher in PyMT/Col1a1 tumors when compared to PyMT tumors and celecoxib reduces tumor volume in PyMT/Col1a1 mice. e The average
amount of glucose uptake by the tumors remains the same regardless of collagen density or treatment with celecoxib. 18Fluorodeoxyglucose (FDG)
positron emission tomography (PET) tracer. %ID/g (tissue) is the percent injected dose of PET tracer per gram of tissue. f Representative PET images of
PyMT/Col1a1 mice at 9 and 14 weeks of age either treated with celecoxib or vehicle. Images over time correspond to same subject. Arrows indicate
tumors and asterisks indicate tissue other than tumors that uptake the FDG tracer, such as brain, carotid, brown fat, heart, kidneys, aorta, bladder, or
muscle tissue. g Regulation of cytokines by density and celecoxib. Several cytokines are upregulated in PyMT/Col1a1 (HD) mammary
tumors compared to PyMT (wild-type (WT)) tumors. Treatment with celecoxib diminishes cytokine levels in PyMT (WT) and PyMT/Col1a1
(HD) mice. Relative levels of cytokines are represented as the fold-change normalized to PyMT (WT) vehicle. Cytokines with equal to or
greater than a 2-fold change are considered significantly upregulated. Three tumors, each from a single animal, were pooled for each
treatment arm to perform the multiplex cytokine ELISA array. TNFa tumor necrosis factor alpha, IGF insulin growth factor, VEGF vascular
endothelial growth factor, IL interleukin, FGFβ fibroblast growth factor beta, IFNy interferon gamma, EGF epithelial growth factor, G-CSF granulocyte-colony
stimulating factor (CSF-2), GM-CSF granulocyte-macrophage colony-stimulating factor (CSF-3), MCP-1 monocyte chemotactic protein 1 (CCL2), MIP-1a
macrophage inflammatory protein 1 alpha (CCL3), SCF stem cell factor, RANTES regulated on activation, normal T cell expressed and
secreted (CCL5), PDGF-ββ Platelet-derived growth factor beta-beta, β-NGF nerve growth factor beta. c-f For the PET studies, n= 3 and for tumor weight
measurement, n = 5 mice; *p< 0.05, **p< 0.01
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COX-2 also regulates increased collagen deposition.
Treatment with celecoxib leads to a reversal of increased
collagen deposition that occurs around tumors, even in
the PyMT/Col1a1 tumors. This finding adds important
insight into the mechanism of desmoplasia often ob-
served around breast tumors. Moreover, these data are
consistent with our observation that celecoxib dimin-
ished matrix deposition. Interestingly, Lyons et al. also
demonstrated that COX-2 inhibition reduces the colla-
gen deposition associated with tumor growth and pro-
gression to metastasis in the involuting mammary gland
[12]. Our results suggest that greater collagen deposition
and elevated levels of COX-2 promote activation of
more αSMA+ fibroblasts, which in turn elicit greater
deposition of collagenous stroma. Moreover, it has been
demonstrated that macrophages are associated with local
regions of collagen deposition in the postpartum involut-
ing mammary gland [45], suggesting that increased
recruitment of macrophages could also contribute to
elevated collagen deposition in PyMT/Col1a1 tumors.
Consistent with this, we observed reduced numbers of
CAF and F4/80+ macrophages when collagen-dense
tumors were treated with celecoxib. These data suggest
a feed-forward mechanism by which a collagen-dense
microenvironment leads to greater COX-2 expression,
increased inflammatory cells and CAF, and in turn, add-
itional increased stromal deposition.
Celecoxib, with its anti-inflammatory effects, is associ-
ated with less risk of endoscopic mucosal injury [46] and
decreased incidence of cardio-renal toxicity [31] com-
pared with ibuprofen. There is evidence that COX-2
inhibitors can decrease breast cancer risk by 16 % [47].
Thus, we tested whether celecoxib might be a candidate
to consider for chemoprevention in women with dense
breast tissue. Using no more than the maximum cele-
coxib dosage recommended by the FDA, we showed that
COX-2 inhibition with celecoxib results in smaller and
fewer tumors than treatment with vehicle alone in
PyMT/Col1a1 mice. In addition, in PyMT/Col1a1 mice,
treatment with celecoxib decreased expression of all 23
cytokines tested in our ELISA array. This indicates that
COX-2 inhibition modulates several immune and stro-
mal cell populations and delays tumor formation and
progression. We recognize that this is not a true chemo-
prevention preclinical finding, as a major limitation of
the PyMT mouse model is that it is a very aggressive
genetically-driven model of mammary carcinoma. Thus,
it would have been impossible to observe complete pre-
vention of mammary tumors in this context.
There is evidence of the effect of celecoxib as a thera-
peutic agent for primary breast cancer. A randomized
controlled phase II clinical trial demonstrated that pre-
operative treatment with celecoxib changes the expres-
sion of several genes at the transcription level in patients
with invasive breast cancer when compared to placebo
[48]. Additionally, Fabi et al. found that treatment with
celecoxib facilitates the tolerability of capecitabine, a
drug that aids in the delivery of the anti-cancer agent 5-
fluorouracil (5-FU) in patients with metastatic breast
cancer. Results from this phase II clinical trial showed
that in patients with COX-2 over-expressing tumors the
time to progression of disease and median overall survival
was significantly longer with celecoxib treatment [49].
Moreover, the increased gene expression of both COX-2
and collagen I is associated with decreased survival and a
shorter time to development of metastasis [12]. Added to
these findings, our results suggest that COX-2 may be an
effective preventive or therapeutic molecular target that
will preferentially benefit women with dense breast tissue.
A clinical trial to study the impact of celecoxib on women
with dense breast tissue and high COX-2 expression
would be of great clinical significance.
Conclusions
Our findings support a mechanism by which COX-2
modulates tumor progression in collagen-dense matrices
and contributes to a more aggressive tumor microenvir-
onment. In addition, in dense mammary tumors, COX-2
inhibition with celecoxib reduces tumor formation and
growth, collagen deposition, and expression of several
cytokines. These findings suggest that COX-2 has a
direct role in modulating tumor progression specifically
in tumors arising within collagen-dense microenviron-
ments, but minimal effects in non-dense microenviron-
ments. As dense breast tissue is a common occurrence,
and promotes more aggressive tumors, these results sug-
gest that COX-2 may be an effective therapeutic target
for women with dense breast tissue.
Additional files
Additional file 1: Figure S1. Tissue segmentation analysis. a-d Images
for the process of tissue segmentation. Algorithms for tissue segmentation, i.e.,
tumor epithelium versus tumor stroma, were created by machine learning
(see “Methods”). a Sample IF image cube of mouse tumor stained with COX-2
(green) and counterstained with DAPI (blue); ×20 objective; scale bar= 100 um.
b Tissue segmentation mask after training the software. Red epithelium, green
stroma, blue other (empty space, debris/artifacts). c Tissue segmentation map
(overlay of tissue segmentation mask and IF image). d Overlay of object cell
count map and tissue segmentation map. Each object (cell) circled in green
was associated with its respective tissue compartment; tumor epithelium or
stroma and debris was associated with the “other” category and not included
in the statistical analysis. (PNG 1438 kb)
Additional file 2: Figure S2. COX-2 inhibition and lung metastasis. a
Lung metastases tend to be increased in PyMT/Cola1a tumors and are
inhibited by celecoxib (n.s.). Gray shading depicts data density graph to
better illustrate differences in data distribution. Veh vehicle, Clxb celecoxib.
Graphs depict raw data; n = 5 mice per arm. (PNG 31 kb)
Additional file 3: Figure S3. Celecoxib diminishes COX2 and PGE2. a
IHC images of COX-2 and PGE2 (DAB) counterstained with hematoxylin; ×40
objective; scale bar = 50 um. b, c Index was calculated by dividing amount
of positive-stained cells over total amount of cells. Graphs depict raw data.
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b COX-2 levels are elevated in PyMT/Col1a1 tumors. Celecoxib diminishes
COX-2 levels in PyMT and PyMT/Col1a1 tumors. c PGE2 levels are elevated
in PyMT/Col1a1 tumors and celecoxib diminishes PGE2 levels in PyMT and
PyMT/Col1a1 tumors; *p < 0.05, **p < 0.01, ****p < 0.0001; n = 5 mice per
arm; at least 8 image fields analyzed per 2–3 tumors per animal; mixed
linear model. (PNG 1241 kb)
Additional file 4: Figure S4. Histology of mammary tumors after FDG-PET
imaging in the early treatment study. Hematoxylin and eosin stained sections
of mammary tumors from PyMT and PyMT/Col1a1 mice at 9 weeks of age,
treated with celecoxib or vehicle. Histological images confirm the
difference in tumor growth between PyMT and PyMT/Col1a1 mice
and tumor growth reduction in PyMT/Col1a1 mice when treated with
celecoxib prior to tumor formation; ×4 objective; scale bar = 0.5 mm.
(PNG 430 kb)
Abbreviations
5-FU: 5-fluorouracil; CAF: cancer-associated fibroblasts; COX-1: cyclooxygenase-1;
COX-2: cyclooxygenase-2; DAB: 3,3-diaminobenzidine; DAPI: 4',6-diamidino-2-
phenylindole; ECM: extracellular matrix; EGF: epithelial growth factor; ELISA: enzyme-
linked immunosorbent assay; EMT: epithelial-mesenchymal transition; FDA: Food
and Drug Administration; FDG: 2′-deoxy-2′-[18F]fluoro-D-glucose; FFPE: formalin-fixed
paraffin embedding; FGFβ: fibroblast growth factor beta; G-CSF: granulocyte-colony
stimulating factor (CSF-2); GM-CSF: granulocyte-macrophage colony-
stimulating factor (CSF-3); HD: Col1a1tm1jae (mice carrying the collagenase
transgene); IF: immunofluorescence; IFNγ: interferon gamma; IGF: insulin
growth factor; IHC: immunohistochemical analysis; IL: interleukin; IL-17A: interleukin
17A; MCP-1: monocyte chemotactic protein 1 (CCL2); MIP-1α: macrophage
inflammatory protein 1 alpha (CCL3); MMTV: mouse mammary tumor virus;
NSAID: non-steroidal anti-inflammatory drug; OSEM: ordered-subset expectation
maximization; PDGF-ββ: platelet-derived growth factor ββ; PET: positron emission
tomography; PGE2: prostaglandin E2; PTGS2: prostaglandin-endoperoxide synthase
2; PyMT: polyomavirus middle T; RANTES: regulated on activation, normal T cell
expressed and secreted (CCL5); SCF: stem cell factor; TACS-3: tumor associated
collagen signature-3; TAMs: tumor-associated macrophages; TANs: tumor-associated
neutrophils; TNFα: tumor necrosis factor alpha; VEGF: vascular endothelial
growth factor; VIM: vimentin; WT: wild-type; αSMA: alpha smooth muscle
actin; β-NGF: nerve growth factor β.
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